Evidence map›Paper›PMID 41136851›Full record

ReviewAdvances in experimental medicine and biology2025

Development of Animal Models for Preclinical Testing of hPSCs Products.

Zhongwen Li, Lingxue Xu, Faguo Sun, Wumei Wei, Shasha Liu, Haoyuan Wang, Qun Ma, Wanren Zhang, Ying Zhang, Wei Li and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhongwen LiKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Lingxue XuKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Faguo SunKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Wumei WeiKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Shasha LiuKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Haoyuan WangKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Qun MaBeijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
Wanren ZhangBeijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
Ying ZhangKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. yingzhang@ioz.ac.cn.
Wei LiKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. liwei@ioz.ac.cn.
Jun WuKey Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. wuxf@ioz.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The preclinical evaluation of human pluripotent stem cells (hPSCs) products is a complex and crucial process, in which the use of animal models plays a pivotal position. Animal models are diverse, possess unique research value and applicability, and can provide abundant data to support the preclinical evaluation of stem cell products. When selecting animal models, various factors need to be considered comprehensively. The models should exhibit similarities to human diseases in terms of anatomical structure, physiological and biochemical characteristics, and pathological features to better simulate stem cell behavior in the human body. The choice of models also needs to consider experimental objectives, the characteristics of stem cell products, and animal welfare and ethical principles. Finally, this review introduces some examples of preclinical evaluation of hPSCs products in animal disease models, including acute lung injury, acute liver failure, Parkinson's disease, Alzheimer's disease, osteoarthritis, membranous nephropathy, corneal alkali damage, and intrauterine adhesions.

Indexed as

Disease Models, AnimalPluripotent Stem CellsStem Cell TransplantationAnimalsHumansAnimal modelsCell therapyHuman pluripotent stem cell productsPreclinical evaluation

Identifiers

PMID41136851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.